This is a regulatory disclosure made by Jubilant Pharmova Limited to the BSE Limited and the National Stock Exchange of India Limited.
The company has intimated that a meeting of its Board of Directors is scheduled to be held on Monday, October 12, 2026.
The primary agenda for the board meeting is to consider and approve the raising of funds. The proposed instruments for fundraising are Non-Convertible Debentures (NCDs) and/or such other securities as may be permitted under applicable laws.
A key part of the agenda is for the board to approve seeking shareholders' approval, as may be required for the proposed fundraising.
The disclosure was signed by Naresh Kapoor, Company Secretary of Jubilant Pharmova Limited, on October 7, 2026, at 19:29:05 IST.
The information has also been made available on the company's website at www.jubilantpharmova.com.
Financial Impact: The disclosure does not quantify the amount of funds to be raised or the potential financial impact. The outcome is subject to board and subsequent shareholder approval.